Notably, DOTA-H-Tz combined with DZ-Lys-TCO achieved higher tumor-to-background ratios than several existing platforms, including the anti-CD11b-TCO/68Ga-NOTA-polypeptide-Tz system reported by Zhang et al. (T/M = 5.94 ± 1.46 at 48 h) [26]. The gene discussed is ITGAM; the disease is neoplasm.